October 9, 2007
European pharmaceutical group Recordati agrees to €135 million acquisition of Orphan Europe, a pharmaceutical group specializing in treating rare diseases.
On October 8, the firm announced that it has advised European pharmaceutical group Recordati in its €135 million agreement to acquire Orphan Europe, a pharmaceutical group specializing in treating rare diseases. Listed on the Italian Stock Exchange and based in Milan, Recordati develops, manufactures and markets a wide range of pharmaceuticals. With operations in France, Germany, Greece, Ireland, Italy, Portugal, Spain and the United Kingdom, this transaction furthers Recordati’s European growth strategy. Paris-based Orphan Europe is represented through subsidiaries in nine European countries, the United Arab Emirates, as well as through representatives offices in seven countries. The Willkie team advising Recordati includes partners Daniel Hurstel and Pierre Ullmann; special European counsel David Tayar; and associates Olivier Lopez, Aurélia Charar and Chloé Mathonnière.
